Oklahoma has a well-known PBM law — the Patient’s Right to Pharmacy Choice Act — but it is not a reimbursement-floor law. It does not tie reimbursement to NADAC or guarantee payment above acquisition cost. Its reimbursement-amount rule is an anti-self-dealing one: a PBM may not pay an independent pharmacy less than it pays a pharmacy it owns or is affiliated with.
The 2025 amendments (SB 773) added a spread-pricing ban and Attorney General enforcement, but still created no cost-based floor. The statute does require MAC transparency and an appeals route, including, on a denied below-cost appeal, that the PBM point to an in-state wholesaler where the drug is available at or below the reimbursement price.